Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.78 |
| ▸ | PRKDC | P78527 | 3/20 | 0.78 |
| ▸ | ATM | Q13315 | 1/20 | 0.78 |
| ▸ | GSK3B | P49841 | 9/20 | 0.77 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.77 |
| ▸ | CDK2 | P24941 | 8/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | GSK3A | P49840 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6617983 | 0.99 | ATR (0.77) | ATRPRKDCATMGSK3BCCNE2 | |
| SCHEMBL6615544 | 0.91 | ATR (0.88) | ATRPRKDCATMGSK3BCCNE2 | |
| SCHEMBL6620408 | 0.90 | ATR (0.79) | ATRPRKDCGSK3BCCNE2CCNE1 | |
| SCHEMBL6619968 | 0.90 | ATR (0.81) | ATRPRKDCGSK3BCCNE2CCNE1 | |
| SCHEMBL3162088 | 0.89 | ATR (0.81) | ATRPRKDCATMGSK3BCCNE2 | |
| SCHEMBL6616717 | 0.89 | ATR (0.82) | ATRPRKDCATMGSK3BCCNE2 | |
| SCHEMBL18177423 | 0.88 | ATR (1.00) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL2226141 | 0.88 | GSK3B (0.72) | ATRPRKDCGSK3BCCNE2CCNE1 | |
| SCHEMBL9907070 | 0.88 | ATR (0.80) | ATRPRKDCGSK3BCCNE2CCNE1 | |
| SCHEMBL2226149 | 0.87 | GSK3B (0.71) | ATRPRKDCGSK3BCCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | claimed |
| EP-1406877-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004475-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| EP-1406877-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004475-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | ATR 1381/4885PRKDC 897/4885ATM 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.